Normas de orientação para utilização de anti-TNFs subcutâneos

 

Texto Completo disponível apenas em PDF

Full text only available in PDF format

 

 

Bibliografia

Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schreiber S, Byczkowski D, Li J, Kent JD, Pollack PF. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007;132:52-65        [ Links ]

E. Domènech, M.Esteves, F. Gomollón, J. Hinojosa, J.Panés, A.Obrador and M.A.Gassul, por el grupo Espanhol en enfermedades de Crohn y colitis ulcerosa (GETECC). Recomendaciones GETECCU 2005 para el uso de Infliximab en la enfermedad inflamatória intestinal. Gastroenterol Hepatol 2005; 28:126-34

Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D,Panaccione R, Wolf D, Pollack P. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology 2006;130:323-33

João Eurico Fonseca, Helena Lucas, Helena Canhão, Raquel Duarte, Maria José Santos, Miguel Villar, Augusto Faustino, Elena Raymundo. Recommendations for the diagnosis abd treatment of latent and active tuberculosis in inflammatory joint diseases candidates for therapy with tumor necrosis factor alpha inhibitors – march 2008 update. Act Reumatol Port 2008; 33; 77-85

Lópes-San Romám, A. Obrador, J. Fortún, P. Munoz and M.A. Gassul, por el grupo Espanol de Trabajo en enfermedad y colitis Ulcerosa (GETECCU). Recomendaciones sobre tuberculosis y tratamiento de la enfermedad inflamatoria intestinal com Infliximab. Actualization 2006. Gastroenterol Hepatol 2006; 29:

Loreto C, Gómez-Reino J, Rodríguez-Valverde V, Montero D, Pascual-Gómes, Martin Mola E, Carreno L, Figueroa M on Behalf of the BIOBDASER Group. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis & Rheumatism 2005; 52:1766-1772

Plosker GL, Lyseng-Williamson KA. Adalimumab: in Crohn’s disease. BioDrugs. 2007;21:125-32.

Sandborn WJ, Hanauer SB, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh DG,Panaccione R, Wolf D, Kent JD, Bittle B, Li J, Pollack PF. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial. Gut 2007;56:1232-9

William J. Sandborn, Paul Rutgeerts, Robert Enns, Stephen B. Hanauer, Jean-Frederic Colombel, Remo Panaccione, Geert D’Haens, Ju Li, Marie R. Rosenfeld, Jeffrey D. Kent, and Paul F. Pollack. Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab. Ann Intern Med. 2007;146:829-838.

Correspondência:

gedi@med.up.pt